Clinical Trial Update: Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Infliximab [Phase 3]

View source ↗

Summary

Phase 3 trial comparing ABP710 to infliximab in moderate to severe rheumatoid arthritis has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• ABP710 (ABP710)
• Infliximab (infliximab)

Snippet

Sponsor: Amgen | Conditions: Arthritis, Rheumatoid | Phase 3 | Status: COMPLETED | Results posted: 2019-08-28